Funding for this research was provided by:
National Center for Advancing Translational Sciences (1KL2TR002554)
National Cancer Institute (R21CA217268)
Received: 7 November 2019
Accepted: 7 February 2020
First Online: 29 March 2020
Ethics approval and consent to participate
: The study protocol is approved by institutional review boards in the United States of America (Duke University Health System, Pro00094010) and Tanzania (Catholic University Health and Allied Services (CUHAS), CREC/292/2018; Lake Zone branch of the National Institute for Medical Research, MR/53/100/566; and the National Health Research Ethics Review Sub-Committee (NatHREC), NIMR/HQ/R.8a/Vol.IX/3096). Changes to the protocol will be communicated via protocol amendment by the study principal investigators. Documentation of informed consent will be obtained from all participants over the age of 18. Patients under the age of 18 will provide assent, while documentation of informed consent will be obtained from their parents or legal guardians.. For historical patients, the institutional review boards have approved a waiver of consent.
: Written consent for publication will be obtained from study participants.
: The authors declare that they have no competing interests.